Newswise — As more and more promising results of clinical trials on vaccination against human papillomaviruses are published, the more likely it becomes that an HPV vaccine will be the first licensed immunization against a sexually transmitted disease. Because UAB researchers are aware of the enormous implications such a vaccine would have, they are attacking the issue in full force. "If we could vaccinate women early, we could hopefully prevent the development of a very large proportion of cervical cancer 20, 30 or 40 years down the road," said Warner Huh, M.D., UAB gynecologic oncologist. UAB researchers are participating in four clinical trials addressing HPV vaccine efficacy and reliable testing methods, as well as several international study projects.

MEDIA CONTACT
Register for reporter access to contact details
TYPE OF ARTICLE
Feature
SECTION
CHANNELS
KEYWORDS
HPV Vaccine Close Reality
COMMENTS | COMMENTING POLICY